The company intends to use the funds to advance its platform that utilizes computer chip technology to conduct a suite of electrical and electrochemical cell-based assays.
Led by CEO Jeffrey Abbott, CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Building upon a suite of technologies licensed from Harvard University, the platform measures and manipulates live cells to produce real-time, high resolution electrical and electrochemical cell-based assays.CytoTronics recently opened office space in the Agility Labs life sciences facility in Boston, MA, which is equipped with private dedicated biosafety level 2 wet biology labs and dry electronics labs, to continue research and further develop its platform.
29/04/2022
